AU2017346879B2 - Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction - Google Patents

Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction Download PDF

Info

Publication number
AU2017346879B2
AU2017346879B2 AU2017346879A AU2017346879A AU2017346879B2 AU 2017346879 B2 AU2017346879 B2 AU 2017346879B2 AU 2017346879 A AU2017346879 A AU 2017346879A AU 2017346879 A AU2017346879 A AU 2017346879A AU 2017346879 B2 AU2017346879 B2 AU 2017346879B2
Authority
AU
Australia
Prior art keywords
days
day
rnai agent
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017346879A
Other languages
English (en)
Other versions
AU2017346879A1 (en
Inventor
David KALLEND
Peter WIJNGAARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60388127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017346879(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2017346879A1 publication Critical patent/AU2017346879A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: THE MEDICINES COMPANY
Priority to AU2023263519A priority Critical patent/AU2023263519B2/en
Application granted granted Critical
Publication of AU2017346879B2 publication Critical patent/AU2017346879B2/en
Priority to AU2026203584A priority patent/AU2026203584A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017346879A 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction Active AU2017346879B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023263519A AU2023263519B2 (en) 2016-10-18 2023-11-09 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction
AU2026203584A AU2026203584A1 (en) 2016-10-18 2026-05-11 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US62/409,816 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US62/422,028 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US62/472,525 2017-03-16
US201762550426P 2017-08-25 2017-08-25
US62/550,426 2017-08-25
PCT/US2017/057218 WO2018075658A1 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023263519A Division AU2023263519B2 (en) 2016-10-18 2023-11-09 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction

Publications (2)

Publication Number Publication Date
AU2017346879A1 AU2017346879A1 (en) 2019-05-23
AU2017346879B2 true AU2017346879B2 (en) 2023-11-30

Family

ID=60388127

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017346879A Active AU2017346879B2 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction
AU2023263519A Active AU2023263519B2 (en) 2016-10-18 2023-11-09 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction
AU2026203584A Pending AU2026203584A1 (en) 2016-10-18 2026-05-11 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023263519A Active AU2023263519B2 (en) 2016-10-18 2023-11-09 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction
AU2026203584A Pending AU2026203584A1 (en) 2016-10-18 2026-05-11 Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction

Country Status (21)

Country Link
US (3) US20180104360A1 (enExample)
EP (2) EP3529360B1 (enExample)
JP (4) JP7181881B2 (enExample)
KR (3) KR20240067272A (enExample)
CN (4) CN119345221A (enExample)
AU (3) AU2017346879B2 (enExample)
CA (1) CA3042423A1 (enExample)
CL (1) CL2019001047A1 (enExample)
DK (1) DK3529360T3 (enExample)
ES (1) ES2982911T3 (enExample)
FI (1) FI3529360T3 (enExample)
HR (1) HRP20240930T1 (enExample)
HU (1) HUE067712T2 (enExample)
IL (1) IL266066A (enExample)
LT (1) LT3529360T (enExample)
MX (2) MX2019004573A (enExample)
PL (1) PL3529360T3 (enExample)
PT (1) PT3529360T (enExample)
RS (1) RS65725B1 (enExample)
SI (1) SI3529360T1 (enExample)
WO (1) WO2018075658A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3340994A1 (en) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
HRP20240930T1 (hr) 2016-10-18 2024-10-11 Novartis Ag Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN110959011B (zh) 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
CN113286888B (zh) * 2019-05-22 2023-12-22 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20230183694A1 (en) 2020-03-16 2023-06-15 Argonaute RNA Limited Antagonist of pcsk9
CN115572726A (zh) * 2021-06-21 2023-01-06 上海君实生物医药科技股份有限公司 一种抑制PCSK9基因表达的siRNA及其用途
WO2023241591A1 (zh) * 2022-06-14 2023-12-21 大睿生物医药科技(上海)有限公司 调控PCSK9基因活性的siRNA分子
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113930A1 (en) * 2006-05-11 2008-05-15 Pamela Tan Compositions and methods for inhibiting expression of the pcsk9 gene
WO2014089313A1 (en) * 2012-12-05 2014-06-12 Alnylam Pharmaceuticals PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3340994A1 (en) * 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
HRP20240930T1 (hr) 2016-10-18 2024-10-11 Novartis Ag Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113930A1 (en) * 2006-05-11 2008-05-15 Pamela Tan Compositions and methods for inhibiting expression of the pcsk9 gene
WO2014089313A1 (en) * 2012-12-05 2014-06-12 Alnylam Pharmaceuticals PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20160017335A1 (en) * 2012-12-05 2016-01-21 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RICARDO, L-L et al., "Atherosclerosis: Recent trials, new targets and future directions", 2015. INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol.192, pages 72-81. *
Robinson, J.G. (J Manag Care Pharm. 2013 Vol. 19(2):139-149). *
The Medicines Company, "The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si", 18 October 2016. [Retrieved from the internet 2/11/2023]. *

Also Published As

Publication number Publication date
BR112019007843A2 (pt) 2019-10-01
SI3529360T1 (sl) 2024-08-30
EP4397311A2 (en) 2024-07-10
AU2026203584A1 (en) 2026-05-28
KR20190077411A (ko) 2019-07-03
JP2022109948A (ja) 2022-07-28
DK3529360T3 (da) 2024-07-15
AU2023263519B2 (en) 2026-02-12
CN119318663A (zh) 2025-01-17
JP2025016469A (ja) 2025-02-04
JP2019531357A (ja) 2019-10-31
US20260108631A1 (en) 2026-04-23
EP3529360B1 (en) 2024-04-17
EP4397311A3 (en) 2024-10-16
MX2024004495A (es) 2024-05-08
KR20240067272A (ko) 2024-05-16
PL3529360T3 (pl) 2024-08-26
JP7850215B2 (ja) 2026-04-22
AU2023263519A1 (en) 2023-12-07
EP3529360A1 (en) 2019-08-28
MX2019004573A (es) 2019-10-07
IL266066A (en) 2019-06-30
JP7566815B2 (ja) 2024-10-15
ES2982911T3 (es) 2024-10-18
PT3529360T (pt) 2024-07-12
FI3529360T3 (fi) 2024-07-11
CA3042423A1 (en) 2018-04-26
LT3529360T (lt) 2024-07-25
US20180104360A1 (en) 2018-04-19
CN119700800A (zh) 2025-03-28
HUE067712T2 (hu) 2024-11-28
AU2017346879A1 (en) 2019-05-23
CN119345221A (zh) 2025-01-24
KR20250171391A (ko) 2025-12-08
JP2026062719A (ja) 2026-04-10
US20210093736A1 (en) 2021-04-01
HRP20240930T1 (hr) 2024-10-11
RS65725B1 (sr) 2024-08-30
CL2019001047A1 (es) 2020-05-08
JP7181881B2 (ja) 2022-12-01
WO2018075658A1 (en) 2018-04-26
CN110088283A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
AU2023263519B2 (en) Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction
O'Donoghue et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
US12453726B2 (en) Methods of using factor B inhibitors
US12427134B2 (en) Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
KR20210047312A (ko) 스타틴-치료 대상체에서 말초 동맥 혈관재개통에 대한 필요성을 감소시키는 방법
JP2026021335A (ja) ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
HK40113597A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
BR112019007843B1 (pt) Métodos para prevenção de eventos cardiovasculares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
EA040947B1 (ru) Способы профилактики явлений со стороны сердечно-сосудистой системы посредством снижения содержания белка пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
Conchinha et al. Familial Hypercholesterolaemia and the Risk of Cardiovascular Events
HK40013430B (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
HK40013430A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법
NZ792465A (en) Methods for preventing cardiovascular events through proprotein convertase
KR20260016529A (ko) Lp(a) 저해제 화합물의 치료적 용도 및 용량
Sinha et al. Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein (a) Levels: A Systematic

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): THE MEDICINES COMPANY

FGA Letters patent sealed or granted (standard patent)